BioNTech, Pfizer Bispecific Data at ASCO
Decision brief
Answer first · skim in under a minute
BioNTech and Pfizer present promising bispecifics data, while FDA's Pazdur highlights potential opportunities. Discover the implications for the pharma sector.
At ASCO 2026, the PD-1/VEGF bispecific antibody race sharpened: Pfizer reported updated Phase 2 NSCLC data for PF-08634404, while BioNTech and Bristol Myers Squibb detailed interim ROSETTA Lung-02 results for pumitamig—two programs now shaping competitive strategy, endpoint design, and partnership calculus across first-line lung cancer.
Contents10 sections
Key Takeaways
- Pfizer’s ASCO 2026 oncology release flagged updated Phase 2 monotherapy data for PD-1/VEGF bispecific PF-08634404 (SSGJ-707) in first-line PD-L1-expressing NSCLC.
- BioNTech and BMS reported interim Phase 2 ROSETTA Lung-02 (NCT06712316) data for pumitamig (BNT327/BMS-986545) plus chemotherapy in previously untreated advanced NSCLC.
- Their 2025 Business Wire partnership commits up to $1.5 billion upfront and shared global development for BNT327 across solid tumors.
- Neither program is FDA-approved on the basis of these ASCO readouts; Phase 3 work continues.
What did Pfizer disclose on its PD-1/VEGF bispecific?
In its May 2026 ASCO press release, Pfizer said it would present updated Phase 2 data for PF-08634404 (also called SSGJ-707), a bispecific antibody targeting PD-1 and VEGF, as monotherapy in first-line PD-L1-expressing NSCLC.
Pfizer positioned PF’4404 as a potential backbone across tumors and noted ongoing Symbiotic-Lung-01 Phase 3 testing with chemotherapy in first-line NSCLC regardless of PD-L1 expression, plus Symbiotic-GI-03 in first-line metastatic colorectal cancer. Exact ORR/PFS numbers belong to the ASCO abstract presentation, not the high-level company preview alone.
What did BioNTech and BMS report for pumitamig?
Pumitamig is an investigational PD-L1xVEGF-A bispecific also known as BNT327 or BMS-986545. The global Phase 2/3 ROSETTA Lung-02 study is listed as NCT06712316 on ClinicalTrials.gov.
Company disclosures around ASCO 2026 described interim Phase 2 activity for pumitamig plus chemotherapy in previously untreated advanced NSCLC, with responses reported across squamous and non-squamous histology and across PD-L1 TPS bands. Those figures are company-reported clinical data, not an FDA label claim.
How large is the BioNTech–BMS bispecific partnership?
On June 2, 2025, BioNTech and Bristol Myers Squibb announced a global co-development and co-commercialization deal for BNT327. Per the Business Wire release, BMS would pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028, with up to $7.6 billion in additional milestones and 50:50 development cost and profit sharing (subject to stated exceptions).
That capital structure explains why pumitamig Phase 3 design choices—endpoint hierarchy, sample size, and combination strategy—matter to both investors and rival PD-1/VEGF sponsors.
Why do Phase 3 endpoint choices matter for FDA strategy?
First-line NSCLC registrational trials still treat overall survival as the gold-standard clinical endpoint, but sponsors sometimes prioritize progression-free survival to accelerate interim discussions. Pfizer’s ASCO materials emphasize OS as a primary endpoint in Symbiotic-Lung-01. BioNTech/BMS Phase 3 designs should be read from protocol documents and ClinicalTrials.gov rather than secondary press summaries.
For BD teams, the practical watch item is whether any program seeks accelerated approval on an earlier endpoint while keeping OS as a key secondary powered analysis. That path is product-specific and must be confirmed in FDA correspondence, not inferred from conference chatter.
What should competitive intelligence teams track next?
- Symbiotic-Lung-01 and Symbiotic-GI-03 enrollment and primary completion dates for PF-08634404.
- ROSETTA Lung-02 Phase 3 transition criteria and any FDA feedback on PFS versus OS hierarchy for pumitamig.
- Cross-trial context versus other PD-1/VEGF bispecifics, including China-only versus global datasets.
- Label-ready safety themes for VEGF-pathway agents (bleeding, hypertension) as Phase 3 matures.
What remains unproven?
These ASCO 2026 disclosures do not establish superiority of either bispecific over approved PD-1 regimens in a global Phase 3 setting. Confirmed response rates from interim Phase 2 cohorts can shrink with longer follow-up. No sourced FDA approval, CRL, or PDUFA date for PF-08634404 or pumitamig is asserted here. Older COVID vaccine asset BNT162b2 is unrelated to these oncology bispecific programs and is not part of this analysis.
Related NovaPharma coverage
- Akeso and Summit Drug Shows Promise in Lung Cancer Trial
- BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
- Revolution Medicines' Pancreatic Cancer Drug: Practice-Changing Results
Frequently Asked Questions
What bispecific antibody programs did Pfizer highlight at ASCO 2026?
Pfizer highlighted updated Phase 2 monotherapy data for PF-08634404 (SSGJ-707), a PD-1/VEGF bispecific antibody, in first-line PD-L1-expressing NSCLC, plus ongoing Symbiotic-Lung-01 and Symbiotic-GI-03 Phase 3 studies.
What is pumitamig and which trial reported ASCO 2026 data?
Pumitamig (BNT327/BMS-986545) is an investigational PD-L1xVEGF-A bispecific co-developed by BioNTech and Bristol Myers Squibb. Interim Phase 2 data from ROSETTA Lung-02 (NCT06712316) in previously untreated advanced NSCLC were presented at ASCO 2026.
Have these bispecific antibodies received FDA approval?
No. As of the ASCO 2026 disclosures cited here, PF-08634404 and pumitamig remain investigational. Phase 3 programs are ongoing; FDA approval status should be confirmed on Drugs@FDA before any commercial claim.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for BNT162b2.
Unlock full calendar →Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
